Literature DB >> 1973636

Neuromuscular and cardiovascular effects of pipecuronium.

F F Foldes1, H Nagashima, H D Nguyen, D Duncalf, P L Goldiner.   

Abstract

Pipecuronium bromide (Arduan) is a bisquaternary, steroid-type neuromuscular blocking agent in clinical use in Eastern Europe. Before its introduction into clinical practice in the USA, in the first phase of this study the neuromuscular potency of pipecuronium was determined under "balanced" and enflurance anaesthesia by the cumulative log dose-response method in 30 patients each. In the second phase the intubation and onset times, clinical duration of the first and repeated doses, spontaneous recovery index, reversibility of its residual neuromuscular effect by an anticholinesterase and its effect on heart rate and blood pressure was compared with the same variables observed in patients, anaesthetized with identical techniques but who had received vecuronium or pancuronium. The neuromuscular potency of pipecuronium was greater under enflurane (ED95 = 23.6 +/- 1.1 micrograms.kg-1 (mean +/- SEM)] than under balanced (ED95 = 35.1 +/- 17 micrograms.kg-1) anaesthesia. Pipecuronium was more potent than vecuronium under both balanced (ED95 = 45.8 micrograms.kg-1) and enflurane anaesthesia (ED95 = 27.4 micrograms.kg-1). Following the administration of 2 x ED95 doses there were no clinically significant differences in the intubation or onset times of pipecuronium, vecuronium and pancuronium. Under balanced anaesthesia the clinical duration of 2 x ED95 dose of pipecuronium (110.5 +/- 0.3 min) or pancuronium (115.8 +/- 8.1 min) were similar and about three times longer than that of vecuronium (36.3 +/- 2.1 min). The recovery indices of pipecuronium (44.5 +/- 8.2 min) and pancuronium (41.3 +/- 4.2 min) were also similar and about three times longer than that of vecuronium (14.3 +/- 1.4 min).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973636     DOI: 10.1007/BF03006324

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  7 in total

1.  First clinical experience with a new neuromuscular blocker pipecurium bromide.

Authors:  O Alánt; K Darvas; I Pulay; J Weltner; I Bihari
Journal:  Arzneimittelforschung       Date:  1980

2.  Human dose-response curves for neuromuscular blocking drugs: a comparison of two methods of construction and analysis.

Authors:  J V Donlon; J J Savarese; H H Ali; R S Teplik
Journal:  Anesthesiology       Date:  1980-08       Impact factor: 7.892

3.  Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action.

Authors:  J E Caldwell; K P Castagnoli; P C Canfell; M R Fahey; D P Lynam; D M Fisher; R D Miller
Journal:  Br J Anaesth       Date:  1988-12       Impact factor: 9.166

4.  Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release.

Authors:  E S Vizi; O Kobayashi; A Töröcsik; M Kinjo; H Nagashima; N Manabe; P L Goldiner; P E Potter; F F Foldes
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

5.  Comparative clinical study of pipecurium bromide and pancuronium bromide.

Authors:  M Boros; J Szenohradszky; G Marosi; I Tóth
Journal:  Arzneimittelforschung       Date:  1980

6.  Clinical experience with a new steroid muscle relaxant: pipecurium bromide.

Authors:  A A Bunjatjan; V I Miheev
Journal:  Arzneimittelforschung       Date:  1980

7.  Presynaptic effect of muscle relaxants on the release of 3H-norepinephrine controlled by endogenous acetylcholine in guinea pig atrium.

Authors:  F F Földes; O Kobayashi; M Kinjo; L G Harsing; H Nagashima; D Duncalf; P L Goldiner; E S Vizi
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

  7 in total
  6 in total

Review 1.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

2.  Neuromuscular effects of pipecuronium during sevoflurane anesthesia compared with isoflurane and enflurane anesthesia.

Authors:  Y Nakao; M Ohno; M Imai; O Kemmotsu
Journal:  J Anesth       Date:  1993-10       Impact factor: 2.078

Review 3.  The use of muscle relaxants in the intensive care unit.

Authors:  M D Sharpe
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

4.  The pharmacodynamics of rocuronium in pediatric patients anesthetized with halothane.

Authors:  G Bikhazi; F Marin; N J Halliday; K Deepika; F F Foldes
Journal:  J Anesth       Date:  1994-09       Impact factor: 2.078

5.  A comparison of pipecuronium with pancuronium on haemodynamic variables and plasma catecholamines in coronary artery bypass patients.

Authors:  P P Neidhart; P Champion; J Vogel; E K Zsigmond; E Tassonyi
Journal:  Can J Anaesth       Date:  1994-06       Impact factor: 5.063

Review 6.  New developments in nondepolarizing muscle relaxants.

Authors:  R K Mirakhur
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.